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Pharmacokinetic (PK) studies in preterm infants are rarely conducted due to the research challenges posed by this population.
To overcome these challenges, minimal-risk methods such as scavenged sampling can be used to evaluate the PK of commonly
used drugs in this population. We evaluated the population PK of metronidazole using targeted sparse sampling and scavenged
samples from infants that were <32 weeks of gestational age at birth and <120 postnatal days. A 5-center study was performed.
A population PK model using nonlinear mixed-effect modeling (NONMEM) was developed. Covariate effects were evaluated
based on estimated precision and clinical significance. Using the individual Bayesian PK estimates from the final population PK
model and the dosing regimen used for each subject, the proportion of subjects achieving the therapeutic target of trough con-
centrations >8 mg/liter was calculated. Monte Carlo simulations were performed to evaluate the adequacy of different dosing
recommendations per gestational age group. Thirty-two preterm infants were enrolled: the median (range) gestational age at
birth was 27 (22 to 32) weeks, postnatal age was 41 (0 to 97) days, postmenstrual age (PMA) was 32 (24 to 43) weeks, and weight
was 1,495 (678 to 3,850) g. The final PK data set contained 116 samples; 104/116 (90%) were scavenged from discarded clinical
specimens. Metronidazole population PK was best described by a 1-compartment model. The population mean clearance (CL;
liter/h) was determined as 0.0397  (weight/1.5)  (PMA/32)2.49 using a volume of distribution (V) (liter) of 1.07  (weight/1.5).
The relative standard errors around parameter estimates ranged between 11% and 30%. On average, metronidazole concentra-
tions in scavenged samples were 30% lower than those measured in scheduled blood draws. The majority of infants (>70%) met
predefined pharmacodynamic efficacy targets. A new, simplified, postmenstrual-age-based dosing regimen is recommended for
this population. Minimal-risk methods such as scavenged PK sampling provided meaningful information related to develop-
ment of metronidazole PK models and dosing recommendations.
Preterm infant pharmacokinetic (PK) studies are exceptionallyscarce due to the research challenges posed by this population,
such as limited blood volume for PK sampling, difficulty in timing
of PK samples due to the critical medical condition of the infants,
difficult access to obtain samples, and low rates of informed pa-
rental consent. Feasibility issues also are imposed by traditional
PK study designs, which require large numbers of specifically
timed PK blood samples. These difficulties have encouraged in-
vestigators to explore novel minimal-risk methods to evaluate the
PK of antimicrobials in this population. One proposed method is
the use of scavenged samples left over from the normal clinical
care of infants. The use of scavenged samples for PK studies in
preterm infants offers several advantages over traditional timed
PK trials. These include avoiding the need for heel sticks specifi-
cally for the study, higher rates of parental consent due to per-
ceived minimal risk, availability of several samples per infant, and
avoidance of time-specific PK sampling (23). This method, com-
bined with collection of timed PK samples (collected specifically
for study purposes), has proven successful in the evaluation of
fluconazole PK in preterm infants (23). To our knowledge, the use
of scavenged samples for PK analysis of other antimicrobials has
not been evaluated.
Metronidazole is approved by the U.S. Food and Drug Admin-
istration for the treatment of adults with serious infections caused
by susceptible anaerobic bacteria but is not approved for use in
children. In spite of this, metronidazole is extensively used “off-
label” in children to treat anaerobic intra-abdominal infections
(i.e., perforated appendicitis) (21). In young infants, its use is
typically restricted to treatment of rare cases of anaerobic bacte-
remia, central nervous system infections, and complicated intra-
abdominal infections such as necrotizing enterocolitis (3, 18). Be-
cause infection in young infants with very low birth weight
(1,500 g) is associated with devastating outcomes, including
death and neurodevelopmental impairment, appropriate dosing
recommendations for agents such as metronidazole for this pop-
ulation are needed.
Metronidazole dosing recommendations for preterm infants
listed in commonly used reference sources for pediatric practitio-
ners are based on a combination of birth weight and postnatal age
(PNA) (20) or birth gestational age (BGA) and postmenstrual age
(PMA) (19). These recommendations are derived from small, sin-
gle-center studies and have not been prospectively evaluated. In
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addition, these dosing regimens are cumbersome due to the dif-
ferent combinations of maturation components required to
choose the most appropriate dose. PMA-based dosing offers an
advantage over current recommendations by simplifying dosing
regimens and potentially providing desired metronidazole con-
centrations over a wider age range. PMA-based dosing has not
been systematically evaluated for metronidazole; however, it has
proven successful for other therapeutics in preterm infants (11,
13, 15).
The present study was conducted to assess the population PK
of intravenous metronidazole using scavenged samples collected
from preterm infants 32 weeks BGA.
MATERIALS AND METHODS
Study design. PK samples for this analysis were obtained from the Anti-
microbial PK in High-Risk Infants trial sponsored by the Pediatric Phar-
macology Research Unit. This trial was a multicenter, prospective, open-
label PK study of antimicrobial agents commonly used in the neonatal
intensive care unit. Infants with a BGA of 32 weeks and 120 days of age
receiving intravenous metronidazole as part of their routine medical care
were enrolled. Metronidazole dosing was determined by the routine clin-
ical practice in each unit, and no exclusion criteria were used. To evaluate
the effect of maturation on metronidazole PK, infants were stratified at
enrollment by BGA: 26 weeks, 26 to 29 weeks, and 30 to 32 weeks. The
study was approved by the institutional review boards at each institution,
and informed consent was obtained from a parent or guardian prior to
enrollment.
The following information was collected for covariate analysis: BGA,
PNA, PMA, weight, sex, race, serum creatinine, and ethnicity. Covariates
that exhibited time-dependent changes (e.g., weight and PNA) were per-
mitted to change with time, and the actual value in the data set reflects the
observations made at each patient visit. Missing weights were assigned,
with the last recorded value being carried forward for up to 7 days. Serum
creatinine was recorded when obtained for clinical care. Missing serum
creatinine values were assigned based on an exponential model of se-
rum creatinine and PMA derived from the data (16).
PK sample collection. A sparse sampling approach was followed in
this study. Samples were divided into two types: scavenged and blood
draw. Scavenged samples were defined as samples obtained without ob-
taining additional blood from the infant. These samples were collected
from the clinical laboratory from discarded blood (heparinized or EDTA
tubes) obtained for routine clinical care. Blood draw samples were defined
as samples obtained by collection of extra blood from the infant. Each
blood draw was approximately 0.3 ml of blood collected in EDTA Micro-
tainers. PK sample collection was planned at the following time points:
immediately prior to metronidazole infusion, immediately after the com-
pletion of infusion (time zero), approximately 1 to 1.5 h after completion
of infusion (1 to 1.5 h), approximately 3 to 4 h after completion of infu-
sion (3 to 4 h), and immediately prior to infusion of the next dose. The
following information was collected for all PK samples: draw date, time,
type of sample (i.e., scavenged versus blood draw), specimen number,
collection tube type, and estimated sample volume. The scavenged sample
information was collected from original source documents (nursing doc-
umentation from the medical record). Both accuracy and completeness of
information regarding scavenged samples were assessed through queries
after metronidazole concentration data were obtained. The duration of
metronidazole infusion was performed according to site routine clinical
care. Samples were refrigerated or placed on ice immediately after collec-
tion and then centrifuged at 1,500  g and 4°C for 10 min. Plasma was
removed and stored at 70°C. Samples from all sites were shipped on dry
ice to Duke University Medical Center, where they were stored at 70°C
prior to analysis. Samples were stored for a maximum of 32 months prior
to analysis.
Bioanalytical assay. A liquid chromatography-tandem mass spec-
trometry assay for metronidazole detection in human plasma suitable for
small plasma volumes was developed and validated (5). Briefly, sample
analysis was performed on an API 4000 triple-quadrupole mass spectrom-
eter (Applied Biosystems–ABSciex, Foster City, CA) operated with elec-
trospray ionization (TurboV source using a TurboIonspray probe). In-
strument parameters were optimized for the metronidazole transition
(172.1¡128.1 m/z). Chromatographic separation was achieved using a
reverse-phase C18 Aquasil column (Thermo Fisher, Waltham, MA) with a
flow rate of 0.75 ml/min using a gradient mobile phase. Mobile phase A
consisted of 0.1% formic acid in water, and mobile phase B consisted of
0.1% formic acid in methanol. Analytical data were acquired by Analyst
software 1.4.1 (Applied Biosystems–ABSciex, Foster City, CA). The lower
limit of quantitation of metronidazole in plasma was 0.05 mg/liter. Intra-
day and interday coefficients of variation were 9.5% at concentrations
ranging from 0.05 to 25 mg/liter.
Population PK analysis. PK data were analyzed with a nonlinear
mixed-effect modeling approach using the computer program NON-
MEM (version 7) in conjunction with WINGS for NONMEM version
7.03 (University of Auckland, Auckland, New Zealand). Output was
summarized using STATA 10 (StataCorp, College Station, TX). The
first-order conditional estimation method with interaction was used
TABLE 1 Dosing schemes used to assess pharmacodynamic target achievementa







The Harriet Lane Handbook 1.2 NA 7 NA NA 7.5 24
1.2–2 NA 7 NA NA 7.5 12
2 NA 7 NA NA 15 12
Neofax NA NA 28 29 15 7.5 48
NA NA 28 29 15 7.5 24
NA NA 14 30–36 15 7.5 24
NA NA 14 30–36 15 7.5 12
NA NA 7 37–44 15 7.5 24
NA NA 7 37–44 15 7.5 12
NA NA ALL 45 15 7.5 6
PMA-based dosing regimen NA 32 NA 34 15 7.5 12
NA 32 NA 34–40 15 7.5 8
NA 32 NA 40 15 7.5 6
a BW, birth weight; GA, gestational age; PMA, postmenstrual age; PNA, postnatal age; NA, not applicable.
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for all model runs. One- and two-compartment structural PK models
were evaluated. Interindividual random effects were evaluated on
clearance (CL) and volume of distribution (V). An exponential model
for interindividual variance was used, and a proportional error model
was deemed appropriate to describe residual variability. The potential
impact of clinical covariates on PK parameters was explored if a rela-
tionship was suggested by visual inspection of scatter and box plots
(continuous and categorical variables, respectively) of individual
Bayesian estimates obtained from the base model and CL interindi-
vidual variability against covariates. The following covariates were
evaluated: weight (kg), BGA (weeks), PNA (days), PMA (defined as GA
plus PNA in weeks [PNA/7]), serum creatinine, race, sex, and ethnic-
ity. A serum creatinine model including an indicator variable (CR)
that excluded a potential outlier with a serum creatinine of 4.7 mg/dl
was also evaluated. Once covariates were identified during the model-
building process, covariate testing was performed via standard for-
ward-addition– backward-elimination methods. Potential covariates
that reduced the objective function by more than 3.84 (P  0.05)
were included in the subsequent multivariable analysis. A forward
inclusion with backward elimination approach was used during the
multivariable step, and a reduction of 6.63 (P  0.01) was required
for retention of a covariate in the final model. Continuous covariates
were scaled to their median values. Empirical Bayesian estimates of
individual infant PK parameters were generated from the final model
TABLE 2 Clinical data by gestational age group
Characteristic
Valuea for group with gestational age at birth (wk)
26 26–29 30–32
n 13 14 5
Gestational age
(wk)
24 (22–25) 28 (26–29) 31 (30–32)
Postnatal age
(days)
53 (7–97) 32 (0–97) 33 (8–71)
Postmenstrual
age (wk)
32 (24–39) 32 (28–43) 36 (32–40)
Weight (g) 1,410 (678–2,537) 1,510 (850–3,611) 1,658 (1,230–3,850)
Female 6 (46) 9 (64) 2 (40)
White race 4 (31) 10 (71) 2 (40)
Hispanic 1 (8) 2 (14) 0 (0)
Serum creatinine
(mg/dl)
0.5 (0.3–4.7) 0.5 (0.2–1.2) 0.2 (0.1–0.6)
Dose (mg/kg) 7.6 (4.2–14.2) 7.8 (6.2–15.1) 9.0 (6.5–15.4)
Dosing
frequency (h)
11.9 (5.9–48.2) 12 (5.9–48) 12.3 (11.2–26.7)
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FIG 1 Final population PK model diagnostic plots, showing observed versus population predictions (A) and individual predictions (B) and weighted residuals
versus population predictions (C) and time (D). In panels A and B, the line of identity is included as a reference. For weighted residuals, a solid line at y  0 is
included as a reference.
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using the post hoc subroutine. Bias introduced by scavenged specimens
was evaluated in the random-effects error model of the final popula-
tion model using a fixed effect parameter (SCAV), as well as different
residual variability estimates for blood draws and scavenged samples.
An indicator variable was used to identify scavenged samples.
Model evaluation. Models were evaluated based on successful mini-
mization, goodness-of-fit plots, precision of parameter estimates, boot-
strap procedures, and visual predictive check. The precision of the final
population PK model parameter estimates were evaluated using nonpara-
metric bootstrapping (1,000 replicates) to generate the 95% confidence
intervals for parameter estimates. For the visual predictive check, the final
model was used to generate 1,000 Monte Carlo simulation replicates of
metronidazole exposure, and simulated results were compared with those
observed in the study. The number of observed concentrations outside the
90% prediction interval for each time point was quantified.
Assessment of dose-exposure relationship. Surrogate pharmacody-
namic (PD) targets for metronidazole against anaerobic bacteria are
poorly defined (10). Therefore, for target exposure, a MIC of 8 mg/liter at
steady state was chosen as the surrogate efficacy target. This MIC target is
consistent with the Clinical and Laboratory Standards Institute-recom-
mended MIC susceptibility breakpoint of metronidazole for anaerobic
organisms (4). Metronidazole trough concentrations at steady state were
predicted for each subject using individual empirical Bayesian estimates
from the final model and dosing prescribed in the study per routine med-
ical care. The proportion of subjects in the study who met the PD target
TABLE 3 Model-building processa
Base model and
univariable
analysis Population model OFV OFV
V V  V  (wt/1.5) 498
CL base model CL  CL  (wt/1.5) 498
PMA CL  CL  (wt/1.5) 
(PMA/32)CL-PMA
484.5 13.5
PNA CL  CL  (wt/1.5) 
(PNA/57)CL-PNA
486.4 11.6
SCR CL  CL  (wt/1.5) 
(0.5/SCR)CL-SCR
483.7 14.3








a CL, clearance; OFV, objective function value; PMA, postmenstrual age; PNA,
postnatal age; SCR, serum creatinine (mg/dl); V, volume of distribution. Weight is
in kg.
FIG 2 Base model scatter plots of CL empirical Bayesian estimates and BGA (A), PNA (B), PMA (C), and serum creatinine (D).
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was calculated by BGA group. In addition, Monte Carlo simulations (n 
1,000) using the final population PK model were used to explore dose-
exposure relationships of commonly used metronidazole dosing recom-
mendations listed in Neofax 2011 (19) and The Harriet Lane Handbook
(20), as well as a newly proposed, simpler dosing regimen based on PMA
(Table 1). When a dosing range was recommended, the highest end of the
range was chosen for the simulations. The proportion of simulated sub-
jects who met the PD target was calculated by BGA group and PNA.
Additionally, Monte Carlo simulations (n  100) using the final pop-
ulation PK model fixed and random-effects estimates were performed
to predict metronidazole concentrations in typical subjects receiving
the newly proposed PMA-based dosing regimen, including a loading
dose. These typical subjects included an infant with a PMA of 26 weeks
(weight, 900 g), one with a PMA of 32 weeks (weight, 1,900 g), one with
a PMA of 36 weeks (weight, 2,800 g), and one with a PMA of 41 weeks
(weight, 3,800 g).
RESULTS
Study population. Thirty-three subjects from five centers were
evaluated for analysis. One subject was excluded from the analysis
because sampling was obtained during drug infusion and no other
samples were collected. The overall median (range) BGA, PNA,
PMA, weight, serum creatinine, and dose were 27 (22 to 32)
weeks, 41 (0 to 97) days, 32 (24 to 43) weeks, 1,495 (678 to 3,850)
g, 0.5 (0.1 to 4.7) mg/dl, and 8 (4 to 15) mg/kg, respectively (Table
2). The majority of subjects were female (17/32 [53%]). Sixteen
(50%) were white, and 4 (9%) were Hispanic.
PK specimens. A total of 3 outlier concentrations (of a total
of 119 [2.5%]) were removed from the analysis due to unreli-
ability of sampling times related to time of flush (n  2) or
sample contamination (n  1). The exclusion of these subjects
and samples resulted in 32 subjects from 5 sites with 116 con-
centrations being used in the modeling process. The median
time of PK sampling was 6.5 (0.5 to 24) hours after dosing, and
the median concentration was 14.5 (1.31 to 68.5) mg/liter. An
average of 3.6 samples per infant (range, 1 to 15) was collected,
and the majority of PK samples were scavenged from the clin-
ical laboratory (104/116, 90%).
Population PK model building. A 1-compartment model
was the appropriate structural PK model for this data set (Fig.
1). Because few samples were obtained within the first few
hours after dosing, intercompartmental clearance was not es-
timated, and a 2-compartment model did not provide a better
fit to the data. Weight was included in the base CL and V
models (Table 3). An estimation of the body size exponent
(weight) was explored as a potential body size model for CL
and V; however, it was excluded due to lack of improvement in
model fit and imprecision around the exponent parameter es-
timate. After weight was incorporated into the base model, it
was not possible to estimate interindividual variability in V. An
evaluation of the model prior to the addition of weight as a
covariate for V demonstrated high shrinkage in V interindi-
vidual variability (47%). This finding suggested that the V in-
terindividual variability parameter estimate deviated from a
normal distribution leading to nonparametric estimation of
this parameter. However, once weight was reincorporated into
the model, the V interindividual variability parameter was es-
timated with a value close to zero via nonparametric methods
and was excluded during the model-building process. Age- and
maturity-related covariates (PNA and PMA) as well as serum
creatinine showed correlation with unexplained CL interindi-
vidual variability (Fig. 2). During the univariable evaluation
(after inclusion of body weight), all age-related covariates as
well as serum creatinine resulted in a significant decrease in the
objective function value (Table 3). The largest drop in objective
function value occurred when serum creatinine was added to
the model. However, when the serum creatinine outlier indi-
cator variable was used, the change in objective function was
not as pronounced as that observed with the addition of mat-
uration covariates. This suggested that the significant associa-
tion between serum creatinine and CL was influenced by an
outlier observation (Table 3). In the multivariable analysis, the
addition of serum creatinine did not improve the model good-
ness of fit, nor did it significantly decrease the objective func-
tion value (Tables 3 and 4). When the bias of scavenged sam-
ples was evaluated in the error model of the final population
PK model, underestimation of metronidazole concentrations
by 30% (95% confidence interval, 10 to 42%) was observed
(Table 4).
Population PK model evaluation. The final model had good









CL (liters/h) CL 0.0397 10.9 0.0307 0.0398 0.0483
V (liters) V 1.07 15.0 0.85 1.12 1.37
CL, PMA CL-PMA 2.49 29.8 1.01 2.57 4.20
SCAV SCAV 0.713 12.3 0.581 0.721 0.899
Interindividual
variance




2 13.5 24.5 0.3 13.3 15.7
Scavenged 1
2 29.0 17.9 23.7 27.8 34.9
a CI, confidence interval; CL, clearance; CV, coefficient of variation; PMA,
postmenstrual age; RSE, relative standard error; V, volume of distribution; SCAV,
scavenged samples.
FIG 3 Visual predictive check of metronidazole concentrations versus time.
Solid black circles represent observed concentrations. The shaded area repre-
sents the 90% prediction interval. Solid and dashed lines represent observed
and predicted median concentrations, respectively.
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precision, as evidenced by relative standard errors around the
parameter point estimates of 11 to 30% and by 95% confidence
intervals generated by bootstrapping (1,000 simulated trials;
997 successful runs) (Table 4). Goodness-of-fit diagnostic
plots for the final model are shown in Fig. 1. The visual predic-
tive check revealed a good fit between observed and predicted
metronidazole concentrations (Fig. 3). Only 7% (8/116) of ob-
served concentrations were outside the 90% prediction inter-
val. The two highest concentrations (60 mg/liter), outside the
90% prediction interval, were observed in two subjects. The
weight-adjusted estimated metronidazole clearance for these
subjects was 0.012 liter/kg/h (5th percentile) and 0.020 liter/
kg/h (25th percentile), respectively, and both subjects were 1
week of age.
Bayesian estimates of CL, V, and half-life. The median indi-
vidual empirical Bayesian estimates for CL, V, and half-life
were summarized by BGA group (Table 5). There was a trend
toward increasing median metronidazole weight-normalized
CL and decreasing half-life with increasing BGA group. Con-
sistent with the PMA covariate influence in the final population
PK model, weight-adjusted metronidazole CL increased with
increasing PMA and decreased with increasing serum creati-
nine (Fig. 4).
Dose-exposure relationship. Over 70% of all infants in-
cluded in this study achieved the PD target (steady-state trough
concentrations  than an MIC of 8 mg/liter) (Fig. 5; Table 2).
In contrast, 70% of subjects across BGA groups achieved the
target when dosing recommendations from Neofax 2011 and
The Harriet Lane Handbook were used in simulated data sets
(Fig. 5 and 6). The smallest proportion of preterm infants who
achieved the PD target was observed in the 30- to 32-week BGA
group and in infants with a PNA of 60 days (Fig. 5 and 6). In
contrast, 90% of subjects regardless of BGA group and PNA
achieved the target when the PMA-based dosing scheme was
used in simulated data sets. Higher steady-state metronidazole
trough concentrations were predicted by the PMA-based dos-
ing regimen compared with the other regimens, and therapeu-
tic concentrations (median) were achieved after a loading dose
on the first day of therapy (Fig. 5 and 7).
DISCUSSION
In the present study, the scavenged sampling technique was
used to successfully develop a population PK model and new
metronidazole dosing recommendations for preterm infants.
The newly proposed PMA-based dosing regimen compared
very favorably against published schemes (19, 20); a higher
proportion (90%) of subjects achieved the therapeutic target
in simulated data sets. The PMA-based dosing scheme was par-
ticularly effective in more mature (30 to 32 weeks) and older
(PNA  60 days) infants, where suboptimal metronidazole
concentrations were achieved when published guidelines were
used in simulated data sets. To achieve higher concentrations
in more mature infants, a PMA cutoff of 34 weeks was chosen
to increase the dosing frequency in the PMA-based dosing reg-
imen. This decision was based upon examination of the rela-
tionship between weight-adjusted CL and PMA (Fig. 4) where,
at 34 weeks, the rate of change in metronidazole CL increased.
A higher proportion of subjects achieved the therapeutic target
with the newly proposed regimen, while trough concentrations
in each BGA group were similar to those observed with current
FIG 4 Weight-normalized metronidazole clearance versus postmenstrual age (A) and serum creatinine (B).
TABLE 5 Individual empirical Bayesian pharmacokinetic parameter estimates by gestational age group
Gestational age
CL (liters/h) CL (liters/h/kg) V (liters) V (liters/kg) Half-life (h)
Median 95% CI Median 95% CI Median 95% CI Median 95% CI Median 95% CI
26 weeks 0.033 0.010, 0.187 0.024 0.010, 0.086 1.00 0.48, 1.81 0.71 NA 20.5 5.7, 49.9
26-29 weeks 0.040 0.012, 0.274 0.026 0.012, 0.076 1.08 0.60, 2.58 0.71 NA 18.6 6.5, 38.7
30-32 weeks 0.071 0.019, 0.285 0.029 0.015, 0.074 1.18 0.88, 2.75 0.71 NA 16.7 6.7, 31.1
Overall 0.041 0.012, 0.274 0.025 0.012, 0.076 1.06 0.54, 2.58 0.71 NA 19.1 6.5, 38.7
CI, confidence interval; CL, clearance; V, volume of distribution.
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routine medical care (Fig. 5). These data suggest that safety
should not be different between the new dosing regimen and
current clinical practice, but further prospective studies are
warranted to verify this finding.
Because the present study did not evaluate efficacy or clini-
cal outcomes, a surrogate PD endpoint was used for the study
population receiving metronidazole as part of routine clinical
care and in simulated data sets. In this study, the majority of
subjects (70%) receiving metronidazole during routine med-
ical care achieved the surrogate PD target for efficacy. In con-
trast, when dosing recommendations published in commonly
used pediatric sources were used in simulated data sets, a lower
proportion of subjects achieved the surrogate PD target. This
finding may be due to higher doses (more frequent administra-
tion) prescribed during routine medical care than in published
regimens and suggests that prescribing practices in the neona-
tal intensive care unit are not driven by these sources (19, 20).
Of five participating centers in this study, two used Neofax 2011
as a reference for metronidazole dosing, two used LexiComp
(17a), and one used unit-specific dosing guidelines. Of note,
the scientific bases for dosing recommendations made by The
Harriet Lane Handbook and Neofax 2011 are limited due to
small sample sizes and incomplete PK sampling.
In adults, metronidazole undergoes extensive hepatic metabo-
lism with subsequent renal elimination (14); the elimination half-
life is 8 h (8), 20% is protein-bound, and the apparent V ranges
between 0.25 and 0.85 liter/kg (8). The hepatic metabolizing and
renal elimination systems undergo ontogenic changes during in-
fancy, resulting in increased CL with increasing size and age (2, 6).
In young infants, metronidazole PK differs substantially from
adults; the elimination half-life is 2- to 3-fold longer, and it de-
creases with increasing GA at birth and PNA (7, 9, 17, 22). Not
surprisingly, in the present model, metronidazole CL increased
proportionally with weight and disproportionally with PMA, and
both covariates explained a substantial amount (80%) of the CL
interindividual variability. This finding is consistent with prior
observations in a metronidazole population PK study of 32 pre-
term infants (PMA, 25 to 38 weeks) using dried blood spots, in
which body weight and PMA explained 93% of the CL interin-
dividual variability (17). The population PK parameter estimates
in the present study are also comparable to those estimated in the
study using dried blood spots (17). Other smaller, single-center
FIG 5 PD target attainment rates by gestational age group. (A) Proportion of study subjects who met the PD target with dosing prescribed during routine medical
care; (B) predicted steady-state (SS) metronidazole trough concentrations in study subjects; (C) proportion of simulated subjects who met PD target with
different dosing schemes; (D) predicted steady-state metronidazole trough concentrations in simulated subjects. The horizontal line in panel C represents an
80% success rate. HL, regimen derived according to The Harriet Lane Handbook; PMA, postmenstrual age dosing regimen.
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studies have also shown similar associations between metronida-
zole CL and maturation and between metronidazole V and weight
(7, 9).
The addition of serum creatinine to the multivariable CL
model did not improve the goodness of fit, nor did it significantly
explain remaining CL interindividual variability. Due to onto-
genic changes in renal function among preterm infants, serum
creatinine is strongly linked with maturational components such
as PMA. This observation likely prevented us from distinguishing
the effect of the maturational component in CL interindividual
variability from serum creatinine in the CL model-building pro-
cess. The population PK model developed in this study performed
well during model evaluation and showed good precision around
parameter estimates. After incorporation of weight as a covariate
for V, the interindividual estimate on V was close to zero. It is
plausible that in the subjects enrolled in this study, weight ex-
plained all the interindividual variability in V. It is also possible
that the data were uninformative for estimating this parameter
due to the use of sparse sampling (1).
The bias introduced by scavenged sampling was quantified in
this study and resulted in an underestimation of metronidazole
concentrations by 30%. This finding suggests that collecting
scavenged samples from the clinical laboratory is a viable strategy
to describe metronidazole PK and is further supported by the
environmental stability of metronidazole for up to 48 h (5, 12).
However, during bootstrap procedures, imprecision was observed
around the scavenged sample fixed parameter estimate (95% con-
fidence interval, 10 to 42%). To more precisely estimate the
amount of bias introduced by scavenged samples, a higher num-
ber of timed samples should be obtained. As expected, the residual
variability estimated for scavenged samples was higher than that
estimated for timed specimens. This finding could be due to
higher documentation errors associated with sampling or dosing
times extracted from the medical record after a scavenged sample
was collected. In addition, information regarding the duration
and conditions under which the samples remained in the clinical
laboratory before freezing were not collected. Delays in these steps
could add to the increased residual variability in scavenged sam-
ples.
In summary, the minimal-risk approach of scavenged PK
sampling was an effective method to describe the population
PK of metronidazole in preterm infants, to identify covariates
that explain CL interindividual variability, and to provide dos-
ing recommendations for this population. After scaling for
size, incorporating PMA as a covariate increased the model fit
and led to a newly proposed, simpler dosing regimen based on
FIG 6 PD target attainment rates by gestational age group and postnatal age in simulated subjects in the 26-week (A), 26- to 29-week (B), and 30- to 32-week
(C) BGA groups. HL, regimen derived according to The Harriet Lane Handbook; PMA, postmenstrual age dosing regimen.
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PMA. Future evaluations of this method should consider the
physicochemical properties of the drug (i.e., drug stability),
more detailed documentation of sample collection and storage
conditions, and simultaneous collection of traditional plasma
samples to fully assess the extent of bias introduced by scav-
enged sampling.
ACKNOWLEDGMENTS
This study was sponsored by the National Institutes of Health through the
Pediatric Pharmacology Research Unit. M. Cohen-Wolkowiez receives
support from NICHD 1K23HD064814-01 and the nonprofit organiza-
tion Thrasher Research Foundation for his work in pediatric clinical phar-
macology and from industry (Pfizer) for neonatal and pediatric drug
development. D. Ouellet is an employee of GSK and has no conflict
of interest. P. B. Smith receives research support from NICHD
1K23HD060040-01 and DHHS-1R18AE000028-01 and from industry
(Astellas Pharma US, CV Therapeutics, Johnson & Johnson, Pangen Bio-
systems, Inc., and Pfizer) for neonatal and pediatric drug development.
L. P. James receives research support from the National Institutes of
Health (NIH)/National Institute of Diabetes and Digestive and Kidney
Diseases (1R01DK075936, 1R01DK081406, 1R01 G1-31616-99), the
NIH/National Center for Research Resources (1UL1RR029884), the
Center for Clinical and Translational Research (2289-2), the NIH
(1R01HD060543-01A1), and the Arkansas Children’s Hospital Research
Institute (10469370). A. Ross has no conflicts to report. J. E. Sullivan
received support from the U.S. government for her work in pediatric
pharmacology (U10 HD045934 05) and from industry (conducts clinical
trials for Merck, Sanofi-Aventis, Pfizer, Roche, Novartis, Novo-Nordisk,
Optimer, Cerexa, Bayer, Trius, GSK, BMS, AstraZeneca, Forest, Mpex,
Menarini, Amgen, Diamyd, Takeda, Genzyme, J&J, Centocor, UCB, Hos-
pira, Purdue, Cadence, Cumberland, Endo, Abbott, P&G, and Eisai; has
also served as a consultant for Merck and Sanofi-Aventis) for neonatal and
pediatric drug development. M. C. Walsh has no conflicts to report. A.
Zadell has no conflicts to report. N. Newman has no conflicts to report.
N. R. White has no conflicts to report. A. D. M. Kashuba receives support
from the U.S. government for work in clinical pharmacology
(1U01AI095031, P30AI37260) and from industry (ViiV, Abbott, Ti-
botec, and Merck) for clinical pharmacology. D. K. Benjamin, Jr.,
receives support from the U.S. government for his work in pediat-
ric and neonatal clinical pharmacology (1R01HD057956-02,
1R01FD003519-01, 1U10-HD45962-06, 1K24HD058735-01, and gov-
ernment contract HHSN267200700051C), from the nonprofit organi-
zation Thrasher Research Foundation for his work in neonatal candi-
diasis, and from industry (Astellas Pharma US, Astra Zeneca,
Biosynexus, Cubist Pharmaceuticals, Johnson & Johnson Pharmaceu-
tical Research & Development, Merck & Co., Pfizer, The Medicines
Company, and UCB Pharma) for neonatal and pediatric drug devel-
opment.
FIG 7 Simulated time-concentration profiles with the proposed PMA dosing regimen in typical subjects. (A) PMA, 26 weeks; weight, 900 g; (B) PMA, 32 weeks;
weight, 1,900 g; (C) PMA, 36 weeks; weight, 2,800 g; (D) PMA, 41 weeks; weight, 3,800 g. The shaded area represents the 90% prediction interval around the
loading dose simulations. Solid and dashed lines represent predicted median concentrations for loading versus no loading dose, respectively.
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